GlassScriptPhysician profile
Geoffrey Starr
NPI 1831118017
$4,305.96
in general payments reported to CMS, 2019-2025
29 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $351 · 2021: $497 · 2022: $461 · 2023: $373 · 2024: $344 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,485.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $690.00 | 2021-2025 | Qulipta, Ubrelvy |
| Sunovion Pharmaceuticals INC. | $473.47 | 2019-2021 | |
| Pfizer INC. | $454.01 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $420.90 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Lundbeck LLC | $337.51 | 2025 | Vyepti, Rexulti |
| Biogen, INC. | $234.58 | 2021-2025 | Tysabri, Vumerity |
| Janssen Pharmaceuticals, INC | $216.78 | 2019 | |
| Amgen INC. | $171.84 | 2025 | Uplizna |
| Neurocrine Biosciences, INC. | $162.58 | 2022-2025 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $145.65 | 2021 | |
| Kyowa Kirin, INC. | $124.44 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $121.17 | 2022-2025 | |
| Lilly USA, LLC | $116.35 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $104.91 | 2022 | |
| Acadia Pharmaceuticals INC | $80.88 | 2021-2025 | Nuplazid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $67.78 | 2025 | Wainua |
| Ucb, INC. | $53.44 | 2025 | Rystiggo |
| Argenx US, INC. | $49.31 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $41.98 | 2025 | Valtoco |
| Genzyme Corporation | $37.82 | 2019-2025 | |
| Insightec,INC | $32.52 | 2025 | Exablate |
| Alexion Pharmaceuticals, INC. | $31.86 | 2025 | Ultomiris |
| Allergan, INC. | $25.34 | 2020 | |
| Acorda Therapeutics, INC | $23.78 | 2019 | |
| Grifols USA, LLC | $22.76 | 2025 | Gamunex-C |
| Life Molecular Imaging LTD | $21.85 | 2025 | Neuraceq |
| Amneal Pharmaceuticals LLC | $20.90 | 2025 | Crexont |
| Impel Pharmaceuticals INC. | $19.89 | 2022 | |
| Travere Therapeutics, INC. | $1.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.